



FOR IMMEDIATE RELEASE

Aptus Endosystems Completes Enrollment in STAPLE-2 Pivotal Study

Advances Breakthrough Technology for Treatment of Aortic Aneurysms

Sunnyvale, CA — **February 10, 2009** — Aptus Endosystems Inc., a medical device company developing advanced technology for the endovascular treatment of aortic aneurysms, today announced it has completed primary enrollment in the STAPLE-2 Pivotal Study of the Aptus Endovascular AAA Repair System. STAPLE-2 is the company's US pivotal clinical study to demonstrate the safety and effectiveness of the Aptus Endovascular AAA Repair System.

"Having been involved with clinical trials for EVAR since the early days of the EVT endograft, the completion of the Pivotal STAPLE-2 study brings the therapy to a new level. This truly novel concept of active proximal fixation using helical "screws" combined with a modular endograft on a very small, flexible delivery system expands the option for endovascular therapy to a greater pool of patients. The one year follow-up outcome data is particularly robust and impressive" observed Ronald Fairman, M.D., Chief, Division of Vascular Surgery and Endovascular Therapy at the Hospital of the University of Pennsylvania and Co-National Principal Investigator for the STAPLE-2 study.

One hundred fifty-five (155) sequential patients were successfully enrolled across 25 U.S. clinical trial sites as part of the study to assess the perioperative and long term performance of the company's unique and proprietary combination of stent graft and endovascular stapling system in the treatment of abdominal aortic aneurysms. Patients enrolled in the study are subject to a 1, 6 and 12 month follow-up review, subsequent to which the company will submit data to the U.S. Food and Drug Administration (FDA) for review under the Pre-Market Approval (PMA) approval process. The company intends to submit its final data module to FDA early next year.

"This endovascular stapling technology facilitates our ability to perform aneurysm repair in a manner that closely approximates the suturing technique that is the foundation of open surgical repair. Having the ability to separately control the fixation of the endograft in a catheter-based technology is a new and clinically important capability relative to improved outcomes for patients", added Manish Mehta, M.D., Director of Endovascular Services and Associate Professor of



Surgery at Albany Medical Center, Albany, NY and Co-National Principal Investigator for the STAPLE-2 Study. “

In the company’s Phase I study (STAPLE-1) 21 patients were enrolled at 5 U.S. institutions, Aptus’ unique endograft design, enabled by the use of its proprietary endovascular stapling system, has produced exceedingly positive clinical outcomes. As presented at the 35th annual Veith Symposium (November 2008), these study results demonstrated that patients experienced no device-related endoleaks (Type I, III or IV) and no device migration as late as 2 years post-procedure for those patients who had reached that follow-up. Additionally, over 90% of patients demonstrated a clinically significant reduction in their aneurysm size as early as six months post-procedure.

“Completing enrollment in the STAPLE-2 Pivotal Study is a significant milestone for Aptus Endosystems and moves us one step closer to U.S. commercialization. The broad based support for the Aptus technology from our clinical investigator group has made this a “best in class” study in the endovascular treatment for aneurysmal disease” said Bob H. Katz, President & CEO, Aptus Endosystems Inc.

About Abdominal Aortic Aneurysms

According to the American Heart Association (AHA) and American College of Cardiology (ACC), aneurysm rupture is the 13th leading cause of death in the US in men over 55, resulting in approximately 15,000 deaths per year. The incidence of aortic aneurysm disease increases every year as the population ages. Early detection and diagnosis is increasingly possible as more sophisticated medical screening methods become available. The National Institutes of Health estimates that three to six percent of men over the age of 60 have some form of AAA. In 2005, more than 21 million American males were over the age of 60, and potentially 630,000 will have an AAA. In January 2007, the SAAVE Act legislation was enacted, which included a provision for Medicare to begin payment for aneurysm screening for all people aged 65 entering the Medicare system in known high risk categories for the development of aneurysmal disease.

About Aptus Endosystems, Inc.

Aptus Endosystems is a privately held medical technology company that has developed advanced technology for the endovascular treatment of aortic aneurysm disease. Founded in 2002, Aptus Endosystems has developed a unique endograft and endovascular stapling system delivered via standard catheter technology. The technology allows surgeons to treat abdominal aortic aneurysms through a minimally invasive approach while still providing the control of an open repair. For more information, please visit www.aptusendosystems.com

###

Media Contact:

Aptus Endosystems, Inc.
Bob H. Katz,
President & CEO
Ph. 408-530-9050, ext. 303
bkatz@aptusendo.com